The Lawn Mower® 4.0 by MANSCAPED™ Now Available Internationally
21.7.2021 16:00:00 EEST | Business Wire | Press release
You ready to rock the landscaped look? Let’s get mowin’. Today, MANSCAPED™ , the global leader and category creator of men’s below-the-waist grooming, announces the international launch of its fourth-generation electric trimmer, The Lawn Mower® 4.0 . Designed and engineered specifically for groin and body grooming, the brand’s newest masterpiece focuses on intelligent functionality, maximum performance and, of course, a superior below-the-waist grooming experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005277/en/
The moment you’ve all been waiting for. Men around the world can now get their hands on MANSCAPED’s fourth-generation groin and body trimmer. (Graphic: Business Wire)
What’s more, The Lawn Mower 4.0 has been integrated into MANSCAPED’s thoughtfully curated bundles for the ultimate self-care routine. The hotly anticipated device and newly elevated kits are now shipping to the United Kingdom, the European Union, Norway, Switzerland, Australia, and New Zealand, in addition to the United States and Canada.
“The global launch of The Lawn Mower 4.0 and our newest packages means getting our latest and most exciting innovations into the hands of millions of men all over the world,” said Paul Tran, Founder and CEO of MANSCAPED. “It’s milestones like these that further advance our vision of driving the movement that changes the face of male grooming — something we’re both humbled by and proud to do every day and with every launch.”
What can you expect with the latest and greatest debuting from the global grooming giant? We’re glad you asked...
The Lawn Mower® 4.0 Groin Trimmer
Proven product attributes and state-of-the-art upgrades come together to make this tool the marquee groin and body trimmer on the market.
Core Features:
- SkinSafe® technology to help reduce the risk of nicks, snags, and tugs
- Powerful 7,000 RPM motor with QuietStroke™ technology
- Rechargeable 600 mAh li-ion battery
- Waterproof design for convenient wet or dry operation
New Enhancements:
- Wireless charging system with electromagnetic induction
- 4000k LED spotlight with diffuser so you can see where you’re trimming
- Cutting-edge ceramic blade to help reduce grooming accidents
- Adjustable trimming guard sizes 1 to 4, with 3, 6, 10, or 13mm settings
- Modern two-toned black finish and powerful packaging presentation
- Travel lock for safety - and racking up frequent flier miles
To up-level your grooming game, or give the greatest gift ever, consider exploring MANSCAPED’s luxury kits that combine The Lawn Mower 4.0 with an array of other top-selling tools, formulations, and accessories. When used together, cleanliness and confidence are abounding.
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver® Ball Deodorant - Avoid stenchy under regions and the dreaded “swamp crotch”; infused with cooling aloe vera, this formulation helps combat sweat and unwanted odor down there
- Crop Reviver® Ball Toner - This spray is the solution for maintaining hygiene and freshness, especially when on-the-go; relieve high-friction areas and post-shave irritation with just a spritz
- This bundle’s free gifts include The Shed premium travel bag and the much acclaimed MANSCAPED™ Boxers made with a microfiber blend
Add another essential men's grooming tool into the mix with this kit featuring MANSCAPED’s premier above-the-waist tool.
- The Weed Whacker® Nose & Ear Hair Trimmer - MANSCAPED redesigned the traditional nose hair taming device by focusing on the highest performance and comfort; equipped with SkinSafe technology, a 9,000 RPM motor, and 360-degree rotary dual-blade system
- The Lawn Mower 4.0 Groin Trimmer
- Crop Preserver Ball Deodorant
- Crop Reviver Ball Toner
- The Shed & MANSCAPED Boxers
To learn more and to purchase any of these new products or packages, visit MANSCAPED.com, a one-stop-shop destination website designed for customers in the United Kingdom, European Union, Norway, Switzerland, Australia, New Zealand, Canada and more regions to come this year.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist, trusted by over 2 million men worldwide. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target, Best Buy, and Macy’s stores throughout the U.S. and Hairhouse locations in Australia. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005277/en/
Contact information
MANSCAPED, Inc.
Allison Frazier, Director of Public Relations
allison@manscaped.com
925-216-2791
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom